https://www.selleckchem.com/pr....oducts/z-vad(oh)-fmk
The prospectively randomized, double-blind BRCA-P trial is currently investigating the preventative effect of denosumab in healthy germline mutation carriers. The prospectively randomized, double-blind BRCA-P trial is currently investigating the preventative effect of denosumab in healthy BRCA1 germline mutation carriers. The phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib is the only approved agent for treating - -mutated, hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced
Like
Comment
Share
